Tumbler Fave Likes ...
Health Care: Drugs
Exact Sciences Corporation (EXAS: NASDAQ)
$10.62 0.06 | 0.57%
05/20/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -52.42M | -28.68M | -11.56M | -9.13M |
| Operating Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 2.89M | -263.00K | 873.00K | -528.00K |
| (Decrease) Increase In Other Current Liabilities | 920.00K | 1.27M | 687.00K | -81.00K |
| (Increase) Decrease In Other Working Capital | 0.00 | 0.00 | -988.00K | -7.19M |
| Other Non-Cash Items | 6.64M | 4.36M | 2.36M | 4.41M |
| Net Cash From Continuing Operations | -44.16M | -27.82M | -13.48M | -12.64M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -44.16M | -27.82M | -13.48M | -12.64M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 58.41M | 46.08M | 10.24M | 16.47M |
| Purchases of Property, Plant & Equipment | -681.00K | -2.12M | -626.00K | -462.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -96.05M | -87.02M | -24.50M | -18.88M |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -38.32M | -43.05M | -14.88M | -2.87M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 1.00M |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 60.14M | 27.90M | 82.79M | 14.79M |
| Repayment of Long-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | -107.00K | 0.00 | 2.40M | 16.70M |
| Net Cash From Financing Activities | 60.04M | 27.90M | 85.19M | 32.49M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -22.44M | -42.97M | 56.83M | 16.99M |
Portfolios with EXAS
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- Contributor22 Biopharma Stocks With Br...
- Contributor8 Health Care Stocks With R...
- Usergdean1
- Userradforj John's SEP & Ta...
- UserBlind Rookie
- Userbbrads Portfolio 1
- Userremodelit Portfolio 1
- UserGoBears Under $5 Stock Picks
- UserMornan
Latest EXAS Headlines from TheStreet
- EXACT Sciences Becomes Oversold (EXAS) 04.18.13 | 12:04 pm
- Exact Sciences Colon Cancer Screen Results Disappoint Wall Street 04.18.13 | 08:04 am
- Biotech Stock Mailbag: Exact Sciences, Galena, Titan, Arena, Breakthrough Therapy 04.12.13 | 06:04 am
- Cramer's Top Stock Picks: ARCP OPK EXAS 04.06.13 | 06:04 am
- Cramer's 'Mad Money' Recap: Next Week's Game Plan 04.05.13 | 07:04 pm
- 6 Stocks Under $10 Spiking Higher 04.04.13 | 03:04 pm
- J.P. Morgan Healthcare Confab Live Blog Day Three 01.09.13 | 10:01 am
- Cramer's Top Stock Picks: NPSP BAC EXAS 01.08.13 | 06:01 am
- Cramer's 'Mad Money' Recap: Safe Harbors for Investment 01.07.13 | 07:01 pm
- 'Mad Money' Lightning Round: Love Infrastructure, Avoid Semiconductors 12.21.12 | 06:12 am
Press Releases for EXAS
- Exact Sciences To Participate In 25th Annual Roth Conference - Business Wire 03.11.13 | 04:03 pm
- Exact Sciences Reports Fourth-Quarter 2012 Financial Results - Business Wire 02.20.13 | 07:02 am
- Exact Sciences Submits Second Module Of Premarket Approval Application To FDA - Business Wire 02.18.13 | 07:02 am
- Exact Sciences To Host Fourth-Quarter, Full-Year 2012 Results Webcast And Call - Business Wire 02.12.13 | 04:02 pm
- Exact Sciences To Participate In February Investor Conferences - Business Wire 02.12.13 | 11:02 am
- Exact Sciences To Participate In J.P. Morgan Healthcare Conference - Business Wire 01.03.13 | 09:01 am
- Exact Sciences Submits First Module Of Premarket Approval Application To FDA - Business Wire 12.10.12 | 04:12 pm
- Exact Sciences To Participate In Canaccord Genuity Medical Technology & Diagnostics Forum - Business Wire 11.29.12 | 12:11 pm
- Senior Research Associate II Tanya Quint At Work In The Exact Sciences' Lab In Madison, Wis. (Photo: Business Wire) - Business Wire 11.15.12 | 07:11 am
- Exact Sciences To Participate In November Investor Conferences - Business Wire 11.07.12 | 10:11 am
Partner Headlines for EXAS
- Testing, Testing: Analyst Kevin DeGeeter On 5 Good Bets In Cancer Diagnostics - Seeking Alpha 11.30.12 | 09:11 am
- Unum INITIATED at Buy and 3 Shares With Analyst-Initiated Coverage - Wall St. Cheat Sheet 07.18.12 | 03:07 am
- UPDATE: Auriga Raises PT to $13 on EXACT Sciences - Benzinga 02.24.12 | 04:02 pm
- Exact Sciences Promotes Arora to Chief Operating Officer - Benzinga 02.16.12 | 04:02 pm
- 10 Undervalued Biotech Stocks With Insider Buying - Seeking Alpha 06.23.11 | 06:06 am
- Momentum Ideas: Friday's High Volume Gainers Chased by Big Money Managers - Seeking Alpha 04.17.11 | 07:04 am
- Cramer's Mad Money - 6 Earnings and IPOs to Watch for the Coming Week (4/8/11) - Seeking Alpha 04.10.11 | 04:04 am
- Life Science Portfolios: Reflecting on a Year of Out-Performance - Seeking Alpha 12.29.10 | 05:12 am
- UPDATE1-New colon cancer test works without colonoscopy - Reuters 10.28.10 | 05:10 pm
- Detecting More Upside Potential for EXACT Sciences - Seeking Alpha 10.22.10 | 09:10 pm
